Secondary Progressive Efficacy Clinical
He also points to the numerous negative trials in primary progressive MS (PPMS), and that responders in recent positive trials with ocrelizumab (PPMS) and siponimod (secondary progressive MS; SPMS) were patients in early stages of progression. The EDMUS cohort averages the rate of progression extracted from a large European database which does not rule out that patients with exacerbations could have slower progression of disease or delayed disability. Second, many of the early European patients received chemotherapy which could affect their long-term disease course. As noted, there is an inflammatory presence in progressive MS that could be a treatment target. One needs to distinguish progression from increased disability due to relapses, admittedly not always doable in progressive disease with superimposed relapses. There is no single pathological mechanism that clearly defines progressive MS, and transition from RMS to SPMS is not sudden nor clear-cut.
The controversy of the benefits of immunomodulatory therapy for progressive MS and whether phenotype may guide decision-making is still unresolved. Our understanding of differences between RMS and progressive MS in treatment, in pathology and pathogenesis has increased but questions remain. Clinical definitions and even imaging definitions are limited, particularly in individual patients. 13 Even with triple dose gadolinium and a 3T magnet, lack of enhancement does not mean cellular entry to the parenchyma has ceased. 14 Inflammation persists in progressive MS but it is different. More research is required into pathological mechanisms of progressive MS.
There are positive trials in progressive MS but there needs to be a discussion between physician and patient in terms of expectations, slowing or possibly prevention of worsening rather than improvement. DMTs have side effects. Patients with progressive MS are more disabled, often older, have more comorbidities, and are taking many medications for MS symptoms and to treat their other illnesses. 15 Therefore, they are likely to suffer these side effects. Patients with progressive MS need to be informed that the inflammatory mechanism of disease is still incompletely understood and there is a neurodegenerative component that cannot be discounted.
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